Worth reading
62In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
19.3
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentation materialsSecond quarter of the fiscal year ending March 202710 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales65,131 Millions of yen+5.9%
Operating profit6,168 Millions of yen+19.3%
Ordinary income5,620 Millions of yen+12.0%
Net income3,578 Millions of yen+13.5%
Operating profit margin9.5%
Selling, general and administrative expenses28,747 Millions of yen
Full-year earnings forecast
Net Sales
133,000 Millions of yen
Cost of sales
62,000 Millions of yen
Gross profit
71,000 Millions of yen
Selling, general and administrative expenses
60,000 Millions of yen
Operating profit
11,000 Millions of yen
EBITDA
22,600 Millions of yen
Ordinary income
10,500 Millions of yen
Profit attributable to owners of the parent
6,500 Millions of yen
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales49.0%
Vision Care48.8%
1DAY50.0%
Domestic 1DAY50.5%
Domestic Mels Plan48.5%
Domestic merchandise sales57.9%
Overseas 1DAY47.2%
Orthokeratology-related51.1%
Other contact lenses and lens care47.6%
Healthcare and Life Care51.8%
Operating profit56.1%
EBITDA50.8%
Ordinary income53.5%
Profit attributable to owners of the parent55.0%
Mels Plan49.6%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progress has been solid and broadly in line with expectationsBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Operating profit
Increase in gross profit+¥1.6 billion
Human resources investment-¥450 million
Advertising and promotional expenses+¥20 million
Other SG&A expenses-¥210 million
Key drivers of gross profit
1DAYAn increase in MELS PLAN membership program members and expanded sales in Japan and overseas
Orthokeratology-relatedExpansion of sales regions and the impact of the weaker yen
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
EUR¥180.0
USD¥155.0
CNY¥22.0
New initiatives
- Strengthening 1DAY supply capacity through a two-factory operating structure
- Expansion of 1DAY sales and production capacity
- Development of medical devices using self-assembling peptides
- Promotion of the green infrastructure business
- Launch of the シアーズ product in May 2026
- Obtaining approval for the ヴァーテ product in February 2026
Key KPIsA metric the company considers important as a management benchmark.
- EBITDA11,473 Millions of yen+14.7%
- EBITDA margin17.6%yoy_change+1.3 percentage points
- Cumulative MELS membership129.8 10,000 people
- 1-Day member composition ratio29.8%
- Average monthly Mels Plan fee3,295 Yen
Unit price and quantity metricsThese figures show sales broken down by price and volume.
1-Day member composition ratio29.8%
Average monthly Mels Plan fee¥3,295
Cumulative MELS membership1.298 million cumulative MELS PLAN membership program members
Segment results
Vision Care
Net Sales
60,471 Millions of yen+5.6%
Healthcare and Life Care
Net Sales
4,660 Millions of yen+10.9%
Medium-term management plan targets
Plan nameVision 2030 / Milestone 2027
Target fiscal yearFiscal year ending March 2028
Net SalesMore than ¥140 billion
ROE12%
Financial targets
ROE
Forecast for the fiscal year ending March 20277%
Target for the fiscal year ending March 202812%
Equity ratio
48.4%
As of30 September 2026
Net debt-to-equity ratio
0.5
As of30 September 2026
Acquisition of treasury shares
¥3 billion (as shown in the cash flow chart)
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2027 |
| Net Sales | 65,131 Millions of yen (YoY +5.9%) |
| Operating profit | 6,168 Millions of yen (YoY +19.3%) |
| Ordinary income | 5,620 Millions of yen (YoY +12.0%) |
| Net income | 3,578 Millions of yen (YoY +13.5%) |
| Operating profit margin | 9.5% |
| Selling, general and administrative expenses | 28,747 Millions of yen |
| Full-year earnings forecast | Net Sales 133,000 Millions of yen / Cost of sales 62,000 Millions of yen / Gross profit 71,000 Millions of yen / Selling, general and administrative expenses 60,000 Millions of yen / Operating profit 11,000 Millions of yen / EBITDA 22,600 Millions of yen / Ordinary income 10,500 Millions of yen / Profit attributable to owners of the parent 6,500 Millions of yen |
| Progress against full-year forecast | Net Sales 49.0% / Vision Care 48.8% / 1DAY 50.0% / Domestic 1DAY 50.5% / Domestic Mels Plan 48.5% / Domestic merchandise sales 57.9% / Overseas 1DAY 47.2% / Orthokeratology-related 51.1% / Other contact lenses and lens care 47.6% / Healthcare and Life Care 51.8% / Operating profit 56.1% / EBITDA 50.8% / Ordinary income 53.5% / Profit attributable to owners of the parent 55.0% / Mels Plan 49.6% |
| Self-assessment against the plan | Progress has been solid and broadly in line with expectations |
| Segment results | Vision Care Net Sales 60,471 Millions of yen (YoY +5.6%) / Healthcare and Life Care Net Sales 4,660 Millions of yen (YoY +10.9%) |
| Breakdown of Factors Affecting the Change | Operating profit Increase in gross profit +¥1.6 billion / Human resources investment -¥450 million / Advertising and promotional expenses +¥20 million / Other SG&A expenses -¥210 million / Key drivers of gross profit 1DAY An increase in MELS PLAN membership program members and expanded sales in Japan and overseas / Orthokeratology-related Expansion of sales regions and the impact of the weaker yen |
| Key KPIs | EBITDA 11,473 Millions of yen (YoY +14.7%), EBITDA margin 17.6%, Cumulative MELS membership 129.8 10,000 people, 1-Day member composition ratio 29.8%, Average monthly Mels Plan fee 3,295 Yen |
| Unit price and quantity metrics | 1-Day member composition ratio 29.8% / Average monthly Mels Plan fee ¥3,295 / Cumulative MELS membership 1.298 million cumulative MELS PLAN membership program members |
| Assumptions Underlying the Business Outlook | Exchange rate EUR ¥180.0 / USD ¥155.0 / CNY ¥22.0 |
| Medium-term management plan targets | Plan name Vision 2030 / Milestone 2027 / Target fiscal year Fiscal year ending March 2028 / Net Sales More than ¥140 billion / ROE 12% |
| Financial targets | ROE Forecast for the fiscal year ending March 2027 7% / Target for the fiscal year ending March 2028 12% / Equity ratio 48.4% / Net debt-to-equity ratio 0.5 |
| Acquisition of treasury shares | Amount ¥3 billion (as shown in the cash flow chart) / Number of Shares Not disclosed / Period Not disclosed |
| New initiatives | Strengthening 1DAY supply capacity through a two-factory operating structure, Expansion of 1DAY sales and production capacity, Development of medical devices using self-assembling peptides, Promotion of the green infrastructure business, Launch of the シアーズ product in May 2026, Obtaining approval for the ヴァーテ product in February 2026 |
Items this document does not state (11)
Gross Profit MarginResults for the three months of the current quarterNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookAnnual DividendPayout ratioCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Growth in gross profit driven by expanded 1DAY sales and other factors, and a review of the cost structure. For 1DAY, increased supply, stronger sales promotion and expanded overseas sales contributed. Meanwhile, selling, general and administrative expenses, including investment in personnel and advertising and sales promotion expenses, increased.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.